Department of Psychology and Neuroscience, University of Colorado, Box 345, Boulder, CO, 80309-0345, USA.
Department of Psychology, University of California, Los Angeles, CA, USA.
Breast Cancer Res Treat. 2022 Oct;195(3):393-399. doi: 10.1007/s10549-022-06705-1. Epub 2022 Aug 12.
Oral anti-cancer medications are increasingly common and endocrine therapies represent the most common oral anti-cancer medications in breast cancer. Adjuvant endocrine therapies reduce the likelihood of recurrence and mortality in the approximately 80% of women diagnosed with hormone-receptor-positive breast cancer, thus rendering adherence essential. Real-time medication adherence monitors, such as the Wisepill electronic pillbox, transmit adherence data remotely, allowing for early intervention for non-adherence. However, their feasibility and acceptability have yet to be examined among breast cancer survivors taking endocrine therapies.
This study presents quantitative patient-report and technical support data and qualitative patient acceptability data on Wisepill, a common real-time adherence monitor, among 88 breast cancer survivors prescribed adjuvant endocrine therapy.
This mixed-methods study of a common real-time adherence monitor, among the first in breast cancer survivors taking adjuvant endocrine therapy, demonstrates its technical feasibility and patient acceptability.
The use of wireless medication monitors that transmit real-time adherence data is uniquely promising for maximizing the benefits of adjuvant endocrine therapy by allowing for continuous tracking, ongoing communication with oncologic or research teams, and early intervention. This study demonstrates the feasibility and patient acceptability of one such real-time adherence monitor.
口服抗癌药物越来越常见，而内分泌治疗是乳腺癌最常见的口服抗癌药物。辅助内分泌治疗降低了大约 80%激素受体阳性乳腺癌患者复发和死亡的可能性，因此坚持治疗至关重要。实时药物依从性监测仪，如 Wisepill 电子药盒，可以远程传输依从性数据，从而可以对不依从的情况进行早期干预。然而，它们在接受内分泌治疗的乳腺癌幸存者中的可行性和可接受性尚未得到检验。
本研究提供了定量的患者报告和技术支持数据，以及定性的患者可接受性数据，研究对象为 88 名接受辅助内分泌治疗的乳腺癌幸存者，他们使用了 Wisepill，这是一种常见的实时依从性监测仪。
这项针对辅助内分泌治疗乳腺癌幸存者的常见实时依从性监测仪的混合方法研究表明，它具有技术可行性和患者可接受性。
使用无线药物监测仪来传输实时依从性数据具有独特的优势，可以通过持续跟踪、与肿瘤学或研究团队的持续沟通以及早期干预，最大限度地提高辅助内分泌治疗的益处。本研究证明了一种实时依从性监测仪的可行性和患者可接受性。
